Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy

por Crane, Christopher H., Varadhachary, Gauri R., Wolff, Robert A., Fleming, Jason B.
Publicado 2009

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

por Raghav, Kanwal, Overman, Michael, Poage, Graham M., Soifer, Harris S., Schnabel, Catherine A., Varadhachary, Gauri R.
Publicado 2020

Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait

por Huey, Ryan W., Makawita, Shalini, Xiao, Lianchun, Matamoros, Aurelio, Estrella, Jeannelyn S., Overman, Michael J., Varadhachary, Gauri R., Raghav, Kanwal
Publicado 2019

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait

por Huey, Ryan W., Smaglo, Brandon G., Estrella, Jeannelyn S., Matamoros, Aurelio, Overman, Michael J., Varadhachary, Gauri R., Raghav, Kanwal P.S.
Publicado 2021

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes

por Raghav, Kanwal, Mhadgut, Hemendra, McQuade, Jennifer L., Lei, Xiudong, Ross, Alicia, Matamoros, Aurelio, Wang, Huamin, Overman, Michael J., Varadhachary, Gauri R.
Publicado 2016

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

por Abdel-Wahab, Reham, Varadhachary, Gauri R., Bhosale, Priya R., Wang, Xuemei, Fogelman, David R., Shroff, Rachna T., Overman, Michael J., Wolff, Robert A., Javle, Milind
Publicado 2018

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival

por Nystrom, J. Scott, Hornberger, John C., Varadhachary, Gauri R., Hornberger, Richard J., Gutierrez, Hialy R., Henner, W. David, Becker, Shawn H., Amin, Mahul B., Walker, Michael G.
Publicado 2012

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

por Douglas, Julia E., Liu, Suyu, Ma, Junsheng, Wolff, Robert A., Pant, Shubham, Maitra, Anirban, Tamm, Eric P., Bhosale, Priya, Katz, Matthew H. G., Varadhachary, Gauri R., Koay, Eugene J.
Publicado 2022

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

por Das, Prajnan, Wolff, Robert A, Abbruzzese, James L, Varadhachary, Gauri R, Evans, Douglas B, Vauthey, Jean Nicolas, Baschnagel, Andrew, Delclos, Marc E, Krishnan, Sunil, Janjan, Nora A, Crane, Christopher H
Publicado 2006

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma

por Liu, Qingqing, Stewart, John, Wang, Hua, Rashid, Asif, Zhao, Jun, Katz, Matthew H., Lee, Jeffrey E., Fleming, Jason B., Maitra, Anirban, Wolff, Robert A., Varadhachary, Gauri R., Krishnan, Sunil, Wang, Huamin
Publicado 2017

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

por Fogelman, David R., Holmes, Holly, Mohammed, Khalil, Katz, Matthew H. G., Prado, Carla M., Lieffers, Jessica, Garg, Naveen, Varadhachary, Gauri R., Shroff, Rachna, Overman, Michael J., Garrett, Christopher, Wolff, Robert A., Javle, Milind
Publicado 2014

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

por Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia
Publicado 2020

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

por Raghav, Kanwal P, Stephen, Bettzy, Karp, Daniel D, Piha-Paul, Sarina A, Hong, David S, Jain, Dipti, Chudy Onwugaje, Dilichukwu O, Abonofal, Abdulrahman, Willett, Anneleis F, Overman, Michael, Smaglo, Brandon, Huey, Ryan W, Meric-Bernstam, Funda, Varadhachary, Gauri R, Naing, Aung
Publicado 2022

The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer

por Perri, Giampaolo, Prakash, Laura, Malleo, Giuseppe, Caravati, Andrea, Varadhachary, Gauri R., Fogelman, David, Pant, Shubham, Koay, Eugene J., Herman, Joseph, Maggino, Laura, Milella, Michele, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Salvia, Roberto, Lee, Jeffrey E., Bassi, Claudio, Katz, Matthew H. G.
Publicado 2020

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

por Katz, Matthew H. G., Varadhachary, Gauri R., Fleming, Jason B., Wolff, Robert A., Lee, Jeffrey E., Pisters, Peter W. T., Vauthey, Jean-Nicolas, Abdalla, Eddie K., Sun, Charlotte C., Wang, Huamin, Crane, Christopher H., Lee, Jeffrey H., Tamm, Eric P., Abbruzzese, James L., Evans, Douglas B.
Publicado 2010

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience

por Goldstein, Jennifer B., Tang, Chad, Hess, Kenneth R., Hong, David, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Karp, Daniel D., Naing, Aung, Tsimberidou, Apostolia Maria, Wheler, Jennifer, Zinner, Ralph, Javle, Milind, Varadhachary, Gauri R., Wolff, Robert A., Fogelman, David R., Meric-Bernstam, Funda, Piha-Paul, Sarina A.
Publicado 2017

Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study

por Zaid, Mohamed, Widmann, Lauren, Dai, Annie, Sun, Kevin, Zhang, Jie, Zhao, Jun, Hurd, Mark W., Varadhachary, Gauri R., Wolff, Robert A., Maitra, Anirban, Katz, Matthew H. G., Herman, Joseph M., Wang, Huamin, Knopp, Michael V., Williams, Terence M., Bhosale, Priya, Tamm, Eric P., Koay, Eugene J.
Publicado 2020

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic...

por Katz, Matthew H G, Petroni, Gina R, Bauer, Todd, Reilley, Matthew J, Wolpin, Brian M, Stucky, Chee-Chee, Bekaii-Saab, Tanios S, Elias, Rawad, Merchant, Nipun, Dias Costa, Andressa, Lenehan, Patrick, Cardot-Ruffino, Victoire, Rodig, Scott, Pfaff, Kathleen, Dougan, Stephanie K, Nowak, Jonathan Andrew, Varadhachary, Gauri R, Slingluff, Craig L, Rahma, Osama
Publicado 2023

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

por Chadha, Awalpreet S., Skinner, Heath D., Gunther, Jillian R., Munsell, Mark F., Das, Prajnan, Minsky, Bruce D., Delclos, Marc E., Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K., Katz, Matthew H., Fleming, Jason B., Javle, Milind M., Wolff, Robert A., Varadhachary, Gauri R., Crane, Christopher H., Krishnan, Sunil
Publicado 2016

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

por Mohindroo, Chirayu, Hasanov, Merve, Rogers, Jane E., Dong, Wenli, Prakash, Laura R., Baydogan, Seyda, Mizrahi, Jonathan D., Overman, Michael J., Varadhachary, Gauri R., Wolff, Robert A., Javle, Milind M., Fogelman, David R., Lotze, Michael T., Kim, Michael P., Katz, Matthew H.G., Pant, Shubham, Tzeng, Ching‐Wei D., McAllister, Florencia
Publicado 2021